Literature DB >> 31662570

CAMTA-1 Expression in 24 Cases of Hepatic Epithelioid Hemangioendothelioma in a Single Institute: Diagnostic Utility for Differential Diagnosis from Hepatic Angiosarcoma.

Hera Jung1, Han-Na Kim1, Yunjeong Jang1, Cheol-Keun Park1,2, Sang-Yun Ha3.   

Abstract

BACKGROUND/AIM: Epithelioid hemangio-endothelioma (EHE) of the liver is an uncommon vascular tumor with variable clinical courses ranging from stable disease to fatal outcome. EHE can mimic epithelioid angiosarcoma, which has a more aggressive behavior, especially in a small biopsy sample. EHEs are known to have the WWTR1-CAMTA1 fusion gene, and nuclear expression of CAMTA1 by immunohistochemistry (IHC) has been reported in about 90% of EHEs in multiple organs. Our study aimed to validate the diagnostic utility of CAMTA1 expression in EHEs, especially in the liver. PATIENTS AND METHODS: IHC was performed using anti-CAMTA1 antibody in 34 tumors (24 hepatic EHEs and 10 angiosarcomas). In CAMTA1-negative EHEs, TFE3 IHC was performed.
RESULTS: Of the 24 hepatic EHEs, 22 (91.6%) showed nuclear staining for CAMTA1. One of two CAMTA1-negative cases showed TFE3 positivity. The other case was negative for TFE3. Meanwhile, all 10 angiosarcoma cases had no CAMTA1 expression.
CONCLUSION: CAMTA1 is a highly sensitive and specific marker for diagnosis of hepatic EHE. It is helpful for differentiation of hepatic EHE and angiosarcoma, especially in small biopsy samples. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  CAMTA1; TFE3; angiosarcoma; cancer; epithelioid hemangioendothelioma; liver; prognosis

Mesh:

Substances:

Year:  2019        PMID: 31662570      PMCID: PMC6899089          DOI: 10.21873/invivo.11736

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  10 in total

1.  CAMTA1 is a useful immunohistochemical marker for diagnosing epithelioid haemangioendothelioma.

Authors:  Ryo Shibuya; Atsuji Matsuyama; Eisuke Shiba; Hiroshi Harada; Kei Yabuki; Masanori Hisaoka
Journal:  Histopathology       Date:  2015-05-22       Impact factor: 5.087

2.  Epithelioid hemangioendothelioma of the liver: a clinicopathologic study of 137 cases.

Authors:  H R Makhlouf; K G Ishak; Z D Goodman
Journal:  Cancer       Date:  1999-02-01       Impact factor: 6.860

3.  A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites.

Authors:  Costantino Errani; Lei Zhang; Yun Shao Sung; Mihai Hajdu; Samuel Singer; Robert G Maki; John H Healey; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2011-05-16       Impact factor: 5.006

4.  Calmodulin-binding transcription activator 1 (CAMTA1) alleles predispose human episodic memory performance.

Authors:  Matthew J Huentelman; Andreas Papassotiropoulos; David W Craig; Frederic J Hoerndli; John V Pearson; Kim-Dung Huynh; Jason Corneveaux; Jürgen Hänggi; Christian R A Mondadori; Andreas Buchmann; Eric M Reiman; Katharina Henke; Dominique J-F de Quervain; Dietrich A Stephan
Journal:  Hum Mol Genet       Date:  2007-04-30       Impact factor: 6.150

5.  Epithelioid hemangioendothelioma of the liver: a clinicopathologic and follow-up study of 32 cases.

Authors:  K G Ishak; I A Sesterhenn; Z D Goodman; L Rabin; F W Stromeyer
Journal:  Hum Pathol       Date:  1984-09       Impact factor: 3.466

6.  Epithelioid hemangioendothelioma: a vascular tumor often mistaken for a carcinoma.

Authors:  S W Weiss; F M Enzinger
Journal:  Cancer       Date:  1982-09-01       Impact factor: 6.860

7.  Nuclear Expression of CAMTA1 Distinguishes Epithelioid Hemangioendothelioma From Histologic Mimics.

Authors:  Leona A Doyle; Christopher D M Fletcher; Jason L Hornick
Journal:  Am J Surg Pathol       Date:  2016-01       Impact factor: 6.394

8.  Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma.

Authors:  Cristina R Antonescu; Francois Le Loarer; Juan-Miguel Mosquera; Andrea Sboner; Lei Zhang; Chun-Liang Chen; Hsiao-Wei Chen; Nursat Pathan; Thomas Krausz; Brendan C Dickson; Ilan Weinreb; Mark A Rubin; Meera Hameed; Christopher D M Fletcher
Journal:  Genes Chromosomes Cancer       Date:  2013-06-05       Impact factor: 5.006

9.  Epithelioid hemangioendothelioma of soft tissue: a proposal for risk stratification based on 49 cases.

Authors:  Andrea T Deyrup; Mourad Tighiouart; Anthony G Montag; Sharon W Weiss
Journal:  Am J Surg Pathol       Date:  2008-06       Impact factor: 6.394

10.  Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma.

Authors:  Munir R Tanas; Andrea Sboner; Andre M Oliveira; Michele R Erickson-Johnson; Jessica Hespelt; Philip J Hanwright; John Flanagan; Yuling Luo; Kerry Fenwick; Rachael Natrajan; Costas Mitsopoulos; Marketa Zvelebil; Benjamin L Hoch; Sharon W Weiss; Maria Debiec-Rychter; Raf Sciot; Rob B West; Alexander J Lazar; Alan Ashworth; Jorge S Reis-Filho; Christopher J Lord; Mark B Gerstein; Mark A Rubin; Brian P Rubin
Journal:  Sci Transl Med       Date:  2011-08-31       Impact factor: 17.956

  10 in total
  3 in total

1.  Hepatic Angiosarcoma: Clinicopathologic Study With an Investigation of ROS1 Gene Rearrangements.

Authors:  Hera Jung; Han-Na Kim; Yunjeong Jang; Cheol-Keun Park; So-Hyun Shin; Sang Yun Ha
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

Review 2.  Angiosarcomas: histology, immunohistochemistry and molecular insights with implications for differential diagnosis.

Authors:  Isidro Machado; Francisco Giner; Javier Lavernia; Julia Cruz; Víctor Traves; Celia Requena; Beatriz Llombart; José Antonio López-Guerrero; Antonio Llombart-Bosch
Journal:  Histol Histopathol       Date:  2020-09-04       Impact factor: 2.303

3.  Three cases of hepatic epithelioid hemangioendothelioma evaluated using conventional and contrast-enhanced ultrasound: Case reports.

Authors:  Jian-Qiang Fang; Ya-Yun Ji; Wei-An Zhao; Cui Pu; Si-Yuan Mi; Bin-Yu Zhang
Journal:  J Clin Ultrasound       Date:  2022-01-12       Impact factor: 0.869

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.